October 26, 2020

Vaccines Market Will Be Hit $ 55.2 Billion By 2027

Introduction

According to the study carried out by Acumen Research & Consulting, “The global Vaccines Market is expected to reach US$ 55.2  Bn in 2027 with a remarkable CAGR of 6.4% from 2020 – 2027”. The market report provides an analysis of the global Vaccines Market for the period 2016-2027, wherein 2020 to 2027 is the forecast period and 2019 is considered as the base year.

The Global Vaccines Market Report for 2020 comprises key factors such as latest developments, drivers of results, key players, and growth rate as well as customer perspectives. A comprehensive overview and observations into trends that impact businesses are provided in this market report, which provides extensive information on industries worldwide and national level. This offers a detailed analysis of the industry in a given period, including its scale, position and forecasts of the overall economy. Also includes the key companies working on this market.

The Final Report will cover the impact analysis of COVID-19, Get FREE SAMPLE PDF (Including Full TOC, Table & Figures)@ https://www.acumenresearchandconsulting.com/request-sample/1599

The segmentation covers every important aspect of the market that is essential for proper profiling and clarification. Additionally, the profiled region includes North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa and these regions are further bifurcated into their respective major economies for detailed analysis.

Market Segmentation as below:

Market By Technology

  • Conjugate Vaccines
  • Inactivated Vaccines
  • Live Attenuated Vaccines,
  • Toxoid Vaccines
  • Recombinant Vaccines

By Indication

  • Dengue
  • DTP
  • Hepatitis
  • HPV
  • Influenza
  • Meningococcal
  • MMR
  • Pneumococcal
  • Polio
  • Rotavirus
  • Varicella

By Type

  • Monovalent
  • Multivalent

By Route of Administration

  • Intramuscular
  • Subcutaneous
  • Oral
  • Others

By Type of Patient 

  • Children
  • Adult

Market By Geography

(Regional Output, Demand & Forecast by Countries)

  • North America (USA and Canada)
  • Europe (UK, Germany, France, Spain and Rest of Europe)
  • Asia Pacific (China, Japan, India, Australia, South Korea and Rest of Asia-Pacific)
  • Latin America (Mexico, Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, South Africa and Rest of MEA).

Along with these, for proper market understanding, the major aspects like economic, social, political, and environmental, along with the major regulations and standards in accordance with the Vaccines Market are covered. For the same, Porter’s five forces model, value chain analysis, cost structure analysis, and player positioning analysis are covered.

Competitive landscape is a vital feature which must be known to all key players. The report provides an overview of the competitive scenario of the global Vaccines Market to align both domestic and global competition. Market analysts have also outlined the overview and the main elements, including processes, production and product selection, of any major player in this global market. The study further analyses the companies based on main factors such as business size, market position, industry growth, sales, amount of production and income.

Who are the key players in the market?

The key players operating in Vaccines Market such as Astellas Pharma Inc., Bavarian Nordic, CSL Limited, Daiichi Sankyo Company, Limited, Emergent BioSolutions, Inc., GlaxoSmithKline plc, Johnson & Johnson, MedImmune, LLC, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation.

Customized Requirements? Inquiry Before Buying? Please Email us at sales@acumenresearchandconsulting.com | Single User License US$ 4500

Overview of the Impact of COVID-19 on this market:

The global economy has an effect of the COVID-19 pandemic, with various sectors facing difficulties like the Vaccines Market and its supply chain. The manufacturers face repeated operations with reduced capacity and shortages around the board. However, the need for reduced supply and continuous growth in order to cope with the pandemic is expected to increase the product deployment.

We are taking persistent efforts to enable your business to continue and develop during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of corona virus outbreak across ventures to assist you to prepare for the future.

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Vaccine
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Vaccine Market By Technology
1.2.2.1. Global Vaccine Market Revenue and Growth Rate Comparison By Technology (2015-2026)
1.2.2.2. Global Vaccine Market Revenue Share By Technology in 2017
1.2.2.3. Conjugate Vaccines
1.2.2.4. Inactivated Vaccines
1.2.2.5. Live Attenuated Vaccines
1.2.2.6. Toxoid Vaccines
1.2.2.7. Recombinant Vaccines
1.2.3. Vaccine Market By Indication
1.2.3.1. Global Vaccine Market Revenue and Growth Rate Comparison By Indication (2015-2026)
1.2.3.2. Global Vaccine Market Revenue Share By Indication in 2017
1.2.3.3. Dengue
1.2.3.4. DTP
1.2.3.5. Hepatitis
1.2.3.6. HPV
1.2.3.7. Influenza
1.2.3.8. Meningococcal
1.2.3.9. MMR
1.2.3.10. Pneumococcal
1.2.3.11. Polio
1.2.3.12. Rotavirus
1.2.3.13. Varicella
1.2.4. Vaccine Market By Type
1.2.4.1. Global Vaccine Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.4.2. Global Vaccine Market Revenue Share By Type in 2017
1.2.4.3. Monovalent
1.2.4.4. Multivalent
1.2.5. Vaccine Market By Route of Administration
1.2.5.1. Global Vaccine Market Revenue and Growth Rate Comparison By Route of Administration (2015-2026)
1.2.5.2. Global Vaccine Market Revenue Share By Route of Administration in 2017
1.2.5.3. Intramuscular
1.2.5.4. Subcutaneous
1.2.5.5. Oral
1.2.5.6. Others
1.2.6. Vaccine Market By Type of Patient
1.2.6.1. Global Vaccine Market Revenue and Growth Rate Comparison By Type of Patient (2015-2026)
1.2.6.2. Global Vaccine Market Revenue Share By Type of Patient in 2017
1.2.6.3. Children
1.2.6.4. Adult
1.2.7. Vaccine Market By Geography
1.2.7.1. Global Vaccine Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.7.2. North America Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.7.3. Europe Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.7.4. Asia-Pacific Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.7.5. Latin America Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.7.6. Middle East and Africa (MEA) Vaccine Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Vaccine Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Vaccine Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Vaccine Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Vaccine Major Manufacturers in 2017

CHAPTER 4. Vaccine Market By Technology
4.1. Global Vaccine Revenue By Technology
4.2. Conjugate Vaccines
4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.3. Inactivated Vaccines
4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.4. Live Attenuated Vaccines
4.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.5. Toxoid Vaccines
4.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.6. Recombinant Vaccines
4.6.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 5. Vaccine Market By Indication
5.1. Global Vaccine Revenue By Indication
5.2. Dengue
5.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.3. DTP
5.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.4. Hepatitis
5.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.5. HPV
5.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.6. Influenza
5.6.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.7. Meningococcal
5.7.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.7.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.8. MMR
5.8.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.8.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.9. Pneumococcal
5.9.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.9.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.10. Polio
5.10.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.10.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.11. Rotavirus
5.11.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.11.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.12. Varicella
5.12.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.12.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 6. Vaccine Market By Type
6.1. Global Vaccine Revenue By Type
6.2. Monovalent
6.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.3. Multivalent
6.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 7. Vaccine Market By Route of Administration
7.1. Global Vaccine Revenue By Route of Administration
7.2. Intramuscular
7.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
7.3. Subcutaneous
7.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
7.4. Oral
7.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
7.5. Others
7.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 8. Vaccine Market By Type of Patient
8.1. Global Vaccine Revenue By Type of Patient
8.2. Children
8.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
8.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
8.3. Adult
8.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
8.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 9. North America Vaccine Market By Country
9.1. North America Vaccine Market Revenue and Growth Rate, 2015 – 2026 ($Million)
9.2. North America Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. U.S.
9.3.1. U.S. Vaccine Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
9.3.2. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
9.4. Canada
9.4.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
9.4.2. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)

CHAPTER 10. Europe Vaccine Market By Country
10.1. Europe Vaccine Market Revenue and Growth Rate, 2015 – 2026 ($Million)
10.2. Europe Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. UK
10.3.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
10.3.2. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
10.4. Germany
10.4.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
10.4.2. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
10.5. France
10.5.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
10.5.2. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
10.6. Spain
10.6.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
10.6.2. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
10.7. Rest of Europe
10.7.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
10.7.2. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)

CHAPTER 11. Asia-Pacific Vaccine Market By Country
11.1. Asia-Pacific Vaccine Market Revenue and Growth Rate, 2015 – 2026 ($Million)
11.2. Asia-Pacific Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. China
11.3.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
11.3.2. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
11.4. Japan
11.4.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
11.4.2. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
11.5. India
11.5.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
11.5.2. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
11.6. Australia
11.6.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
11.6.2. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
11.7. South Korea
11.7.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
11.7.2. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
11.8. Rest of Asia-Pacific
11.8.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
11.8.2. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)

CHAPTER 12. Latin America Vaccine Market By Country
12.1. Latin America Vaccine Market Revenue and Growth Rate, 2015 – 2026 ($Million)
12.2. Latin America Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. Brazil
12.3.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
12.3.2. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
12.4. Mexico
12.4.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
12.4.2. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
12.5. Rest of Latin America
12.5.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
12.5.2. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)

CHAPTER 13. MIDDLE EAST & AFRICA VACCINE MARKET BY COUNTRY
13.1. Middle East & Africa Vaccine Market Revenue and Growth Rate, 2015 – 2026 ($Million)
13.2. Middle East & Africa Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
13.3. GCC
13.3.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
13.3.2. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
13.4. South Africa
13.4.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
13.4.2. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
13.5. Rest of Middle East & Africa
13.5.1. Market Revenue and Forecast By Technology, 2015 – 2026 ($Million)
13.5.2. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)

CHAPTER 14. COMPANY PROFILE
14.1. Astellas Pharma Inc.
14.1.1. Company Snapshot
14.1.2. Overview
14.1.3. Financial Overview
14.1.4. Product Portfolio
14.1.5. Key Developments
14.1.6. Strategies
14.2. Bavarian Nordic
14.2.1. Company Snapshot
14.2.2. Overview
14.2.3. Financial Overview
14.2.4. Product Portfolio
14.2.5. Key Developments
14.2.6. Strategies
14.3. CSL Limited
14.3.1. Company Snapshot
14.3.2. Overview
14.3.3. Financial Overview
14.3.4. Product Portfolio
14.3.5. Key Developments
14.3.6. Strategies
14.4. Daiichi Sankyo Company, Limited
14.4.1. Company Snapshot
14.4.2. Overview
14.4.3. Financial Overview
14.4.4. Product Portfolio
14.4.5. Key Developments
14.4.6. Strategies
14.5. Emergent BioSolutions, Inc.
14.5.1. Company Snapshot
14.5.2. Overview
14.5.3. Financial Overview
14.5.4. Product Portfolio
14.5.5. Key Developments
14.5.6. Strategies
14.6. GlaxoSmithKline plc
14.6.1. Company Snapshot
14.6.2. Overview
14.6.3. Financial Overview
14.6.4. Product Portfolio
14.6.5. Key Developments
14.6.6. Strategies
14.7. Johnson & Johnson
14.7.1. Company Snapshot
14.7.2. Overview
14.7.3. Financial Overview
14.7.4. Product Portfolio
14.7.5. Key Developments
14.7.6. Strategies
14.8. MedImmune, LLC
14.8.1. Company Snapshot
14.8.2. Overview
14.8.3. Financial Overview
14.8.4. Product Portfolio
14.8.5. Key Developments
14.8.6. Strategies
14.9. Merck & Co., Inc.
14.9.1. Company Snapshot
14.9.2. Overview
14.9.3. Financial Overview
14.9.4. Product Portfolio
14.9.5. Key Developments
14.9.6. Strategies
14.10. Mitsubishi Tanabe Pharma Corporation
14.10.1. Company Snapshot
14.10.2. Overview
14.10.3. Financial Overview
14.10.4. Product Portfolio
14.10.5. Key Developments
14.10.6. Strategies
14.11. Others
14.11.1. Company Snapshot
14.11.2. Overview
14.11.3. Financial Overview
14.11.4. Product Portfolio
14.11.5. Key Developments
14.11.6. Strategies

CHAPTER 15. RESEARCH APPROACH
15.1. Research Methodology
15.1.1. Initial Data Search
15.1.2. Secondary Research
15.1.3. Primary Research
15.2. Assumptions and Scope

The report is readily available and can be dispatched immediately after payment confirmation.

The Final Report will cover the impact analysis of COVID-19, Download Full Study Report (Single User License US$ 4500)@ https://www.acumenresearchandconsulting.com/buy-now/0/1599

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact-based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Contact Us:

Saurabh S.

Email: sales@acumenresearchandconsulting.com

Phone: +14079154157 | +14089009135

Website: https://www.acumenresearchandconsulting.com

Follow Us: LinkedIN | Twitter

Saurabh

Saurabh is an SEO Analyst professional, working on a large marketing and sales platform that helps firms attract visitors and close customers. Proficient in monitoring and evaluating search results and search performance across the major search channels. With his strong analytical skills. Saurabh covers healthcare, technological, chemical, lifestyle and trendy news from all over the world.

View all posts by Saurabh →

Leave a Reply

Your email address will not be published. Required fields are marked *